131 related articles for article (PubMed ID: 32498877)
1. Electrochemical immunomagnetic assay as biosensing strategy for determination of ovarian cancer antigen HE4 in human serum.
Mattarozzi M; Giannetto M; Careri M
Talanta; 2020 Sep; 217():120991. PubMed ID: 32498877
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
3. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
4. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
5. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
[TBL] [Abstract][Full Text] [Related]
6. Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance.
Yuan J; Duan R; Yang H; Luo X; Xi M
Int J Nanomedicine; 2012; 7():2921-8. PubMed ID: 22745553
[TBL] [Abstract][Full Text] [Related]
7. An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma.
Szymanska B; Lukaszewski Z; Zelazowska-Rutkowska B; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Sensors (Basel); 2021 May; 21(10):. PubMed ID: 34065481
[TBL] [Abstract][Full Text] [Related]
8. A Self-Calibrating IoT Portable Electrochemical Immunosensor for Serum Human Epididymis Protein 4 as a Tumor Biomarker for Ovarian Cancer.
Bianchi V; Mattarozzi M; Giannetto M; Boni A; De Munari I; Careri M
Sensors (Basel); 2020 Apr; 20(7):. PubMed ID: 32260240
[TBL] [Abstract][Full Text] [Related]
9. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors.
Gasiorowska E; Kluz T; Lipski D; Warchoł W; Tykarski A; Nowak-Markwitz E
Dis Markers; 2019; 2019():3890906. PubMed ID: 31583027
[TBL] [Abstract][Full Text] [Related]
10. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
11. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
12. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
15. Electrochemical quantum dots-based magneto-immunoassay for detection of HE4 protein on metal film-modified screen-printed carbon electrodes.
Cadkova M; Kovarova A; Dvorakova V; Metelka R; Bilkova Z; Korecka L
Talanta; 2018 May; 182():111-115. PubMed ID: 29501129
[TBL] [Abstract][Full Text] [Related]
16. Serum Human Epididymis Protein 4 is Associated with Renal Function and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus.
Zhang M; Zhao B; Xie J; Liang Y; Yang Z
Biomed Res Int; 2019; 2019():4831459. PubMed ID: 31815140
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
18. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
[TBL] [Abstract][Full Text] [Related]
19. Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients.
Chudecka-Głaz A; Rzepka-Górska I; Wojciechowska I
Eur J Gynaecol Oncol; 2012; 33(4):382-90. PubMed ID: 23091895
[TBL] [Abstract][Full Text] [Related]
20. Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
Lof P; van de Vrie R; Korse CM; van Gent MDJM; Mom CH; Rosier-van Dunné FMF; van Baal WM; Verhoeve HR; Hermsen BBJ; Verbruggen MB; Hemelaar M; van de Swaluw AMG; Knipscheer HC; Huirne JAF; Westenberg SM; van der Noort V; Amant F; van den Broek D; Lok CAR
Gynecol Oncol; 2022 Aug; 166(2):284-291. PubMed ID: 35688656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
